Login

Join Now

Recent BioUtah News & Events

Everything Happening in Utah Life Sciences

September 28, 2023
BioUtah News
New Myriad Genetics Survey Shows Breast Cancer Risk Factors Are Misunderstood

New Myriad Genetics Survey Shows Breast Cancer Risk Factors Are Misunderstood

September 28, 2023
BioUtah News
Medical Technology Company Focused on Vessel Preparation, Dilation, And Treatment Delivery Secures Series B Funding

Medical Technology Company Focused on Vessel Preparation, Dilation, And Treatment Delivery Secures Series B Funding

September 28, 2023
BioUtah News
Biomerics Announces Completion of 100,000 sq. ft. Expansion of Brooklyn Park, MN, Facility

Biomerics Announces Completion of 100,000 sq. ft. Expansion of Brooklyn Park, MN, Facility

September 28, 2023
BioUtah News
Audio-based Detection of Anxiety and Depression via Vocal Biomarkers

Audio-based Detection of Anxiety and Depression via Vocal Biomarkers

September 28, 2023
BioUtah News
bioMérieux submits Dual 510(k) and CLIA-waiver application to FDA for the BIOFIRE® SPOTFIRE® Respiratory/Sore Throat (R/ST) Panel

Marcy-l’Étoile (France), September 22nd, 2023 – bioMérieux, a world leader in the field of in vitro diagnostics, has submitted the BIOFIRE® SPOTFIRE® Respiratory/Sore Throat (R/ST) Panel to U.S. Food and Drug Administration (FDA) for a dual 510(k) clearance and CLIA1-waiver. This panel is already CE-marked (IVDD2).

September 21, 2023
BioUtah News
Myriad Genetics and Illumina Achieve Milestones in Strategic Partnership to Support Biopharma Clinical Trials

Myriad can conduct prospective clinical trials using Illumina’s TruSight Oncology Comprehensive Investigational Use Only test SALT LAKE CITY, Sept. 19, 2023 (GLOBE NEWSWIRE) — Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced two key milestones in its strategic partnership with Illumina Inc. (NASDAQ: ILMN), a global leader in […]

September 21, 2023
BioUtah News
Myriad Genetics Issues 2022 Environmental, Social and Governance Report

SALT LAKE CITY, Sept. 19, 2023 (GLOBE NEWSWIRE) — Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today released its second annual Environmental, Social and Governance report, highlighting key efforts that reflect its commitment to conduct operations as a responsible, equitable and sustainable partner in the healthcare industry. “At Myriad, […]

September 21, 2023
BioUtah News
Rep. Moore’s Health Staff Visits Utah Life Sciences Companies

Rep. Moore’s Health Staff Tours Visits Utah Life Sciences Companies

September 21, 2023
BioUtah News
Partnership and innovation help SSM Health secure lower-cost, reliable supply of generic drugs

Civica Rx, a health care utility co-founded by SSM Health, supplies critical medications that patients need.

September 21, 2023
BioUtah News
September 21, 2023
BioUtah News
BioUtah, Life Sciences Innovators Take Stage at Legislature’s Interim Meeting

The Utah Life Sciences Innovation Caucus hosted a lunch for all legislators during the September 18.

September 21, 2023
BioUtah News
NUSANO APPOINTS INDUSTRY EXPERT ALEXANDRE GIBIM AS CHIEF OPERATIONS OFFICER

EXECUTIVE WITH THREE DECADES OF SUCCESSFUL MULTINATIONAL OPERATIONS AND COMMERCIAL EXPERIENCE TO LEAD LAUNCH OF PROPRIETARY RADIOISOTOPE PRODUCTION PLATFORM

September 14, 2023
BioUtah News
BioUtah Participates in American Cancer Society Policy Panel Presentation

Kelvyn Cullimore, BioUtah’s CEO, participated as a panelist.

September 7, 2023
BioUtah News
Merit Medical Launches the Aspira® Evacuated Drainage Bottle

Advanced design complements comprehensive drainage portfolio, expanding compassionate at-home treatment options to more patients

September 7, 2023
BioUtah News
Recursion Announces Completion of Phase 1 Study for REC-3964 for Clostridioides Difficile Infection

REC-3964 has been well tolerated in healthy volunteers with no reported serious adverse events. Recursion to explore initiating a Phase 2 proof-of-concept study in patients with recurrent Clostridioides difficile infection in 2024.

September 7, 2023
BioUtah News
New Myriad Genetics Survey Reveals Widespread Confusion and Misconceptions About Ovarian Cancer Screening Among a Majority of Women

Nearly three out of four women falsely believe a pap smear will reveal ovarian cancer presence

September 7, 2023
BioUtah News
Myriad Genetics Named to 2023 Best Workplaces in Health Care List by Fortune and Great Place To Work

Myriad Genetics announced Great Place To Work® and Fortune magazine have named Myriad Genetics to the 2023 Fortune Best Workplaces in Health Care™ List.

September 7, 2023
BioUtah News
Ultradent Named a Fortune Magazine Top Workplace for Third Straight Year

Ultradent Products is being recognized for the third consecutive year as a Fortune Magazine Top Large Workplace in Manufacturing and Production.

August 31, 2023
BioUtah News
Academia in Action: Searching for rare disease treatments

By their very nature, rare diseases impact a smaller portion of the population compared to conditions like cancer or the flu. While these diseases are less common, those affected by them, along with University of Utah researchers, are actively searching for a cure. Treating patients as individuals: Clement Chow Read more about Clement Chow’s research […]

August 31, 2023
BioUtah News
CLENE REPORTS SIGNIFICANTLY IMPROVED SURVIVAL BENEFIT OF 19.3 MONTHS AND SIGNIFICANTLY DELAYED CLINICAL WORSENING IN RESCUE-ALS OPEN-LABEL EXTENSION TWO YEAR FOLLOW-UP

19.3 month significant survival difference for CNM-Au8® treated participants versus placebo 52% significant decreased risk of ALS clinical worsening events Over 475 years of CNM-Au8 treatment exposure without any identified safety signals SALT LAKE CITY, Aug. 29, 2023 (GLOBE NEWSWIRE) — Clene Inc. (Nasdaq: CLNN) through its wholly owned subsidiary Clene Nanomedicine Inc., today announced […]

August 31, 2023
BioUtah News
BioTuesdays Features Halia Therapeutics CEO

In a recent interview with BioTuesdays, Halia and Co-Founder David Bearss, P.HD., said that the company is “growing to become a leader in targeting the NLRP3 inflammasome through a unique mechanism of action.” Closely-held Halia Therapeutics is developing a broad pipeline of novel therapies that are essential mediators of immune cell signaling with the potential […]

August 24, 2023
BioUtah News
Final Demolition Efforts Underway at The Point

Crews to topple final guard tower and showcase sustainable demolition practices   WHAT: Members of the media are invited to get a close-up look at demolition efforts currently underway at The Point. Attendees will get exclusive views of the preserved prison chapel called the “Chapel by the Wayside” and the state-of-the-art crushing facility used to […]

August 24, 2023
BioUtah News
Halia Therapeutics Celebrates Grand Opening of Its Lehi, Utah Headquarters

It was standing room only Tuesday as Halia Therapeutics held a ribbon cutting for the opening of its new headquarters in Lehi, Utah – a 20,000 square foot state-of-art drug research and development facility. CEO and co-founder, David Bearss, Ph.D. welcomed guests and shared the Halia mission: to develop novel therapies to improve the lives […]

August 24, 2023
BioUtah News
Myriad Genetics and Onsite Women’s Health Partner to Help More Women Understand Breast Cancer Risk

New collaboration increases access to genetic testing and can help identify patients with a high-risk for breast cancer SALT LAKE CITY, Aug. 22, 2023 (GLOBE NEWSWIRE) — Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, and Onsite Women’s Health, a leading national provider of breast health services, today announced the […]